R&D Sponsored The importance of time: Grifols seeks biomarkers for early d... Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
